Stock Research: NATCO Pharma

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

NATCO Pharma

NSEI:NATCOPHARM INE987B01026
95
  • Value
    95
  • Growth
    3
  • Safety
    Safety
    67
  • Combined
    100
  • Sentiment
    16
  • 360° View
    360° View
    95
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Natco Pharma Limited is an India-based vertically integrated pharmaceutical company focused on research and development, manufacturing, and commercialization of complex pharmaceuticals. It operates in Pharmaceuticals and Agro chemicals, specializing in catering to niche markets and offering solutions for complex medical needs. It has nine manufacturing facilities across India and two research centers in Telangana, selling products to international markets such as Brazil, Europe, and the United States of America. In the last fiscal year, the company had a market cap of $2128 million, profits of $438 million, and revenue of $518 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 95 (better than 95% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock NATCO Pharma are very positive. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for NATCO Pharma. The consolidated Value Rank has an attractive rank of 67, which means that the share price of NATCO Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 67% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 95. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 16. Professional investors are more confident in 84% other stocks. The consolidated Growth Rank also has a low rank of 3, which means that the company is below average in terms of growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. 97 of its competitors have better growth. ...read more

more
Index
SDG 1
SDG 2
SDG 3
SDG 4
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
67 85 83 75
Growth
3 69 100 33
Safety
Safety
95 91 97 77
Sentiment
16 53 92 10
360° View
360° View
95 99 100 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
15 23 40 19
Opinions Change
2 21 50 50
Pro Holdings
n/a 70 100 44
Market Pulse
35 62 85 37
Sentiment
16 53 92 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
67 85 83 75
Growth
3 69 100 33
Safety Safety
95 91 97 77
Combined
100 100 100 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
89 100 100 76
Price vs. Earnings (P/E)
41 58 61 41
Price vs. Book (P/B)
69 78 78 65
Dividend Yield
53 69 66 72
Value
67 85 83 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
1 74 84 100
Profit Growth
8 76 90 26
Capital Growth
47 69 81 31
Stock Returns
9 23 75 31
Growth
3 69 100 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
78 60 74 66
Refinancing
79 80 84 74
Liquidity
84 80 68 65
Safety Safety
95 91 97 77

Similar Stocks

Discover high‑ranked alternatives to NATCO Pharma and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

L&T Finance Holdings

BSE:533519
Country: India
Industry: Other Financial Services
Size: Medium
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.